Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 358, Issue 11, Pages 1129-1136Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa0707330
Keywords
-
Categories
Funding
- CIHR [62931, 105268, 44289, 36494] Funding Source: Medline
Ask authors/readers for more resources
The glomerular microvasculature is particularly susceptible to injury in thrombotic microangiopathy, but the mechanisms by which this occurs are unclear. We report the cases of six patients who were treated with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in whom glomerular disease characteristic of thrombotic microangiopathy developed. To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, we used conditional gene targeting to delete VEGF from renal podocytes in adult mice; this resulted in a profound thrombotic glomerular injury. These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available